1,850,348 Shares in ProQR Therapeutics N.V. $PRQR Purchased by Aberdeen Group plc

Key Points

• Aberdeen Group plc has acquired 1,850,348 shares of ProQR Therapeutics, representing approximately $2.46 million and about 1.76% ownership in the company.
• ProQR Therapeutics reported a quarterly loss of ($0.14) EPS, missing the expected ($0.08) EPS, with revenue of $4.33 million against an expected $5.01 million.
• Several analysts have maintained a positive outlook for ProQR Therapeutics, with a consensus target price of $8.00 and an average rating of "Buy" for the stock.

Aberdeen Group plc acquired a new position in ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,850,348 shares of the biopharmaceutical company's stock, valued at approximately $2,461,000. Aberdeen Group plc owned about 1.76% of ProQR Therapeutics at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Persistent Asset Partners Ltd purchased a new position in ProQR Therapeutics in the 1st quarter worth approximately $64,000. Monaco Asset Management SAM boosted its holdings in shares of ProQR Therapeutics by 59.1% during the 1st quarter. Monaco Asset Management SAM now owns 471,908 shares of the biopharmaceutical company's stock worth $628,000 after purchasing an additional 175,290 shares during the last quarter. OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 45.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 12,500 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in shares of ProQR Therapeutics during the 1st quarter worth approximately $48,000. Finally, Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $39,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PRQR shares. Cantor Fitzgerald restated an "overweight" rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Evercore ISI restated an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. JMP Securities restated a "market outperform" rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Oppenheimer lowered their target price on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Finally, Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $8.00.

ProQR Therapeutics Stock Performance

PRQR stock opened at $2.21 on Friday. The firm has a market cap of $232.51 million, a PE ratio of -4.80 and a beta of 0.43. The firm's 50 day moving average price is $2.13 and its 200-day moving average price is $1.87. ProQR Therapeutics N.V. has a one year low of $1.07 and a one year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The firm had revenue of $4.33 million for the quarter, compared to analysts' expectations of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. Equities research analysts predict that ProQR Therapeutics N.V. will post -0.31 EPS for the current fiscal year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.